


Observational Research on Hormones and Dementia

Problems of Bias and Confounding (and Preliminary Results)



Terminology

◆ E estrogen alone

◆ EP estrogen plus progestin

Hormones & Cognition/Dementia

Many Questions

- ◆ Does E prevent cognitive dysfunction following oophorectomy at a young age?
- ◆ Does E or EP prevent cognitive dysfunction that occurs during the perimenopause?
 - Is this due to an effect on symptoms and/or dysphoria?

Hormones & Cognition/Dementia

Many Questions

- ◆ Does E or EP improve cognition in women with dementia?
- ◆ Does E or EP prevent the decline in cognition that occurs with aging?
- ◆ Does E or EP alter progression of MCI to dementia?
- ◆ Does E or EP prevent the development of dementia?

Hormones & Cognition/Dementia


Many Questions

- ◆ Does E or EP use starting in the perimenopause and continued into older ages prevent cognitive decline and / or the development of dementia
- ◆ Does long-term E or EP use prevent cognitive decline and / or the development of dementia?
- ◆ Is an effect of E or EP on dementia different between different preparations or by mode of administration?

Hormones & Cognition/Dementia

Many Questions

- ◆ Does E or EP use prevent AD but cause vascular dementia?



Hormone & Cognition/Dementia

Many Biases

- ◆ Proxy bias : Women with dementia / CI cannot reliably report on their prior use of E / EP and so the study relies on proxies for information about E / EP use; but proxies are not able to provide this information (missing information) or under-report prior E / EP use

Hormone & Cognition/Dementia

Many Biases

◆ Proxy bias

- Affects case-control and cross-sectional studies most
- Can be overcome by enrolling only those who self-report and/or by study designs that rely on independent ascertainment of exposure (chart review/record linkage)

ERT and Cognition/Dementia

Many Biases

- ◆ Dementia bias : Women with CI / dementia are asked about their hormone use; but because of their memory problems they may under-report their prior use of E / EP

Women's Memory Study

Hormone Use by Prescription Compared with Self-reported Hormone Use

User by Prescription

	<u>Unimpaired</u>	<u>CI</u>	<u>Dementia</u>
Self-Report			
Ever User	93.8 %	85.8 %	80.9 %
Never User	6.2 %	13.4 %	17.7 %
Not sure	0.0 %	0.8 %	4.2 %

ERT and Cognition/Dementia

Many Biases

◆ Dementia bias :

- Can be overcome by study designs that rely on independent ascertainment of exposure (chart review/record linkage)
- Means that cohort studies must enroll for follow-up only women who are unimpaired at baseline


Hormones & Cognition/Dementia

Many Biases


- ◆ Chicken Egg bias

◆ Chicken / Egg bias


Current E/EP Use



No Dementia



◆ Chicken / Egg bias



Current E/EP Use



No Dementia

Hormones & Cognition/Dementia

Many Biases

◆ Chicken Egg bias

- Cannot be overcome in conventional case-control or cross-sectional studies

Hormones & Cognition/Dementia

Confounders

- ◆ SES
- ◆ Education

- ◆ Antioxidant use
- ◆ Statin use
- ◆ Aspirin use
- ◆ NSAID use

Hormones & Dementia/Cognition

Confounders

- ◆ Uncontrolled and uncontrollable confounding:
Differences between E / EP users that are
unmeasured (and unmeasurable)

e.g., “Lifestyle”

KP Case-Control Study of E / EP and Vascular Disease

Adjusted Odds Ratio for MI (N=565 cases)

	<u>OR (95% C.I.)</u>
Use sunblock or sunscreen	0.54 (0.43-0.68)

Petitti and Sidney, unpublished

E / EP and CHD

Bias or Confounding

- ◆ Compliance : Women who use E / EP are compliant with the taking of medication; compliance is a marker for other differences in behavior that put women (and men) at lower risk of CHD

Coronary Drug Project

Adjusted RR of Incident CHD in Men According to Compliance with Clofibrate Treatment

Clofibrate

Compliance	<u>% Mortality</u>	<u>RR</u>
<80%	22.5	
>80%	15.7	0.7

N Engl J Med 1980;303:1038-1041

Coronary Drug Project

Adjusted RR of Incident CHD in Men According to Compliance with Clofibrate Treatment

	Clofibrate		Placebo	
Compliance	<u>% Mortality</u>	<u>RR</u>	<u>% Mortality</u>	<u>RR</u>
<80%	22.5		28.2	
>80%	15.7	0.7	15.1	0.6

N Engl J Med 1980;303:1038-1041

Beta-Blocker Heart Attack Trial

Adjusted RR of Incident CHD in Women According to Compliance with Treatment

Compliance	Beta-Blocker		Placebo	
	<u>% Mortality</u>	<u>RR</u>	<u>% Mortality</u>	<u>RR</u>
<75%	8.7		19.0	
≥75%	4.5	0.5	6.8	0.4

JAMA 1993;270:742-744

Women's Memory Study

Prospective Study of Dementia in Long-Term Hormone Users

Explicit attempt to overcome proxy bias, dementia bias, and to study long-term hormone use started at an early age

Women's Memory Study

Prospective Study of Dementia in Long-Term Hormone Users

- ◆ Hormone use for primary analysis (per protocol) based on information from computer-stored outpatient prescriptions filled in KPSC pharmacies

Women's Memory Study

Prospective Study of Dementia in Long-Term HRT Users

- ◆ Women defined as hormone user if they had 1 or more prescriptions for oral estrogen recorded in the prescription database in every year from 1992-1998

- 1,944 E / EP users



Women's Memory Study

Prospective Study of Dementia in Long-Term Hormone Users

- ◆ Women defined as hormone non-user if they had no prescriptions for oral estrogen recorded in the prescription data in any year from 1992-1998
 - 1,980 non-users at baseline

Women's Memory Study

Prospective Study of Dementia in Long-Term Hormone Users

- ◆ Classification with dementia, CI, or as unimpaired based on telephone assessment (Telephone Interview of Cognitive Status modified and Telephone Dementia Questionnaire) supplemented with chart review

Women's Memory Study

Comparison of classification using TICSm and TDQ with “gold standard” dementia work-up at USC ADRC

	Dementia/Not	Dementia/CI/Normal
Sensitivity		
for dementia	0.83	0.83
Sensitivity		
for CI	---	0.50
Specificity	1.00	0.93
KAPPA	0.88	0.67

Women's Memory Study

Type and duration of hormone use at entry to the follow-up among hormone users by prescription

	<u>Mean (yrs)</u>	<u>SD</u>
E	29.0	<u>±</u> 11.6
EP	21.6	<u>±</u> 10.9

Women's Memory Study

Age at start of hormone use among hormone users by prescription, % distribution

	<u>E</u>	<u>EP</u>
<46	42	19
46-55	40	40
56-60	8	13
61+	10	27

Percents may not sum to 100 because of rounding

Preliminary Results


Follow-up year four of women without dementia at baseline

<u>Age at Entry</u>	<u>Total N</u>	Incident <u>Dementia</u>	<u>Rate</u>
75-79	1999	160	8.0
80-84	732	86	11.7
85+	175	27	15.4

Preliminary Results


Follow-up year four of women without dementia at baseline

<u>Education</u>	<u>Total N</u>	<u>Incident Dementia</u>	<u>Rate</u>
< High School	331	44	13.3
HS+	2575	229	8.9



Preliminary Results

Follow-up year four of women without dementia at baseline



<u>Hormone Use</u>	<u>Incident Dementia</u>
Non-user	117
E	108
EP	48

Women's Memory Study

Limitations

- ◆ Some women classified as non-users may have used hormones in the past
- ◆ Dementia classification did not involve “gold standard” assessment
- ◆ EP users may used E only in the distant past

Women's Memory Study

Strengths

- ◆ Many very long-term users who began use at an early age
- ◆ Free of proxy bias and dementia bias
- ◆ Loss to follow-up minimized using dementia assessment

Observational Research

Hormones and Dementia:

Future

- ◆ Study of long-term, early exposure will require observational research; experimental studies will become observational as women select in and out of hormone use outside the protocol

Observational Research

Hormones and Dementia:

Recommendations

- ◆ Case-control designs may not be capable of yielding valid results for the question of hormone use and the development of dementia

Observational Research

Hormones and Dementia:

Recommendations

- ◆ Cohort studies should enroll subjects who are dementia free at baseline
- ◆ Independent confirmation of hormone use is highly desirable
- ◆ Loss to follow-up must be minimized

Observational Research

Hormones and Dementia:

Observation

- ◆ It is important to decide whether it is important to know the effect of hormones in AD separate from an effect on all dementia if hormones (some formulations and some modes of administration) increase the risk of stroke (subclinical and clinical) and dementia due to it

Acknowledgment

This research is supported by a grant RO1-AG-14745 from the National Institute on Aging

Co-investigators are Valerie Crooks, Helena Chui, and Galen Buckwalter

Vicki Chiu did the programming